Most Active

Helus Pharma Phase 3 Depression Trial Succeeds But Stock Drops 21% on the Day

Read this in the Market Flux app

Helus Pharma Inc. $HELP

$7.69-13.11%as of publication

5D Change
-17.80%
Notional
$97.22M

Helus Pharma reported positive topline results from its Phase 3 APPROACH study of HLP003, a deuterated psilocin compound, as an adjunctive treatment for adults with major depressive disorder. The drug met its primary endpoint with a placebo-adjusted reduction of 7.6 points on the Montgomery-Asberg Depression Rating Scale at Week 6, with a p-value below 0.0001, and that effect was sustained at 7.0 points through Week 12. The 222-participant trial enrolled patients with moderate-to-severe MDD, defined as a MADRS score of 24 or higher, who were on a stable antidepressant but responding inadequately.

All key secondary endpoints were also met. Response rates at Week 6 were 56.3% for HLP003 versus 28.2% for placebo, and remission rates were 50.9% versus 18.2%. Onset of effect was observed as early as Day 2. Three treatment-related serious adverse events were reported. HLP003 holds Breakthrough Therapy Designation from the FDA, and results from a second Phase 3 study, EMBRACE, are expected in the fourth quarter of 2027.

Despite jumping 23.2% in premarket trading, shares reversed sharply and fell roughly 21% to 26.8% by the open, a pattern common in clinical-stage names where investors sell into trial-success news. Separately, Helus Pharma, which operates under the former Cybin Inc. corporate entity, reported second-quarter fiscal 2027 financial results on the same day, posting a net loss of $103.1 million for the quarter ended September 30, 2026, with cash on hand of $171.1 million.

© AI-generated summary is provided by Market Flux

Sources

  1. BioStocks$HELP topline data from Phase 3 APPROACH pivotal study of HLP003 in MDD in Q4 Cash $171M
  2. BriefingcomGapping up: $LXEO +46.6% $OCS +12.9% $DRTS +10.6% $IDYA +6.6% $ZYME +3.7% Gapping down: $HELP -26.8% $SMMT -13.8% $POET -8.7% $WULF -5.2%
  3. OpenOutcrier$HELP (+23.2% pre) Helus Pharma reports positive phase 3 trial results for HLP003
  4. BPharmCatalyst$HELP announced positive Phase 3 APPROACH data for HLP003 (deuterated psilocin) as an adjunct in major depressive disorder (n=222). The trial met its primary endpoint with a 7.6-point placebo-adjusted MADRS reduction at Week 6 (p<0.0001), sustained at 7.0 points through Week 12. Week 6 response and remission rates were 56.3% and 50.9% versus 28.2% and 18.2% for placebo, with onset by Day 2. Three treatment-related SAEs occurred; Phase 3 EMBRACE results are expected in Q4 2027. $ACRS $LXEO $CRDF $OCS $HELP $DRTS $AKAN $INAB $XRTX $ADXN See More Pre-market Movers at BioPharmCatalyst in the Articles Menu
  5. BenzingaHelus Pharma Touts Positive Data for Depression Drug
  6. NasdaqCybin Inc. Reports Second Quarter Fiscal 2027 Financial Results